TNFSF10 and diabetes mellitus: The first studies establishing a role for TRAIL in diabetes were carried out in animal models of type 1 diabetes mellitus (T1DM), where TRAIL blockade significantly accelerated diabetes development and the degree of autoimmune inflammation [6].